Jennison Associates
FLXN

Jennison Associates’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Jennison Associates’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-19,174
Closed -$516K – 671
2017
Q1 		$516K Sell
19,174
-824
-4% -$16.8K ﹤0.01% 606
2016
Q4 		$380K Sell
19,998
-570
-3% -$10.9K ﹤0.01% 706
2016
Q3 		$402K Buy
+20,568
New +$348K ﹤0.01% 618
2016
Q1 		– Sell
-2,907,755
Closed -$56M – 680
2015
Q4 		$56M Buy
2,907,755
+76,487
+3% +$1.33M 0.06% 268
2015
Q3 		$42.1M Buy
2,831,268
+736,261
+35% +$17.3M 0.04% 332
2015
Q2 		$45.9M Buy
2,095,007
+91,594
+5% +$1.85M 0.04% 353
2015
Q1 		$45.1M Buy
2,003,413
+255,588
+15% +$5.92M 0.04% 342
2014
Q4 		$35.3M Buy
1,747,825
+886,991
+103% +$16.1M 0.03% 378
2014
Q3 		$15.7M Buy
860,834
+40,157
+5% +$581K 0.01% 455
2014
Q2 		$11.1M Buy
820,677
+90,878
+12% +$1.24M 0.01% 471
2014
Q1 		$12M Buy
+729,799
New +$12.6M 0.01% 481

Other funds holding FLXN

GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Jennison Associates's FLXN Position: Q2 2017 in Review

Jennison Associates sold out of Flexion Therapeutics, Inc. (FLXN) in Q2 2017, closing a stake of 19,174 shares — an estimated $516K sold.

Jennison Associates first reported a position in FLXN in Q1 2014 and held it in 11 quarters. The position peaked at $56M in Q4 2015. 100 funds tracked by Wall St. Rank hold FLXN as of Q2 2017.

  • Jennison Associates reported no remaining Flexion Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Jennison Associates sold 19,174 Flexion Therapeutics, Inc. shares in Q2 2017, an estimated $516K.
  • Jennison Associates first reported a position in Flexion Therapeutics, Inc. in Q1 2014 and held it in 11 quarters.
  • Jennison Associates's Flexion Therapeutics, Inc. position peaked at $56M in Q4 2015.
  • 100 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q2 2017.

Based on Jennison Associates's 13F filing for Q2 2017, filed 4 Aug 2017.